다가백신 시장 보고서(2026년)

Multivalent vaccines are formulated to safeguard against multiple strains or types of one pathogen, or even several distinct pathogens, all in a single shot. They incorporate antigens from different strains or diseases to build immunity against numerous targets at once, delivering wider protection than monovalent vaccines that target just one strain or pathogen.

The primary categories of multivalent vaccines include conjugate vaccines, inactivated and subunit vaccines, live attenuated vaccines, toxoid vaccines, and recombinant vaccines. Conjugate vaccines connect a less potent antigen to a more robust one, boosting immune detection and efficacy, especially against bacterial infections. They target conditions like influenza, pneumonia, hepatitis, meningitis, and rotavirus, delivered via routes such as oral or injectable. These vaccines serve multiple age demographics, including children, adults, and seniors, and are available through channels like hospital pharmacies, retail pharmacies, and online pharmacies.

Tariffs have impacted the multivalent vaccines market by increasing the cost of imported biologic raw materials, antigens, and specialized manufacturing equipment used in complex vaccine production. These effects are most pronounced in developing regions that rely heavily on imported inputs for large scale immunization programs. Rising tariff related expenses have placed pressure on public health budgets and vaccine procurement planning. In some markets, this has contributed to delays in vaccine tenders and rollout schedules. However, tariffs are also encouraging domestic vaccine production, technology transfer initiatives, and stronger local supply chains to improve long term vaccine availability.

The multivalent vaccines market research report is one of a series of new reports from The Business Research Company that provides multivalent vaccines market statistics, including multivalent vaccines industry global market size, regional shares, competitors with a multivalent vaccines market share, detailed multivalent vaccines market segments, market trends and opportunities, and any further data you may need to thrive in the multivalent vaccines industry. This multivalent vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The multivalent vaccines market size has grown strongly in recent years. It will grow from $9.12 billion in 2025 to $9.97 billion in 2026 at a compound annual growth rate (CAGR) of 9.4%. The growth in the historic period can be attributed to global immunization initiatives, high burden of infectious diseases, government vaccination programs, improvements in cold chain infrastructure, public health awareness campaigns.

The multivalent vaccines market size is expected to see strong growth in the next few years. It will grow to $14.28 billion in 2030 at a compound annual growth rate (CAGR) of 9.4%. The growth in the forecast period can be attributed to rising focus on pandemic preparedness, increasing elderly population, growth in recombinant vaccine technologies, expansion of universal immunization coverage, increased healthcare funding. Major trends in the forecast period include rising demand for broad-spectrum immunization, increasing focus on combination vaccines, expansion of pediatric and geriatric vaccination programs, growing adoption of preventive healthcare measures, higher investment in vaccine r&d pipelines.

The increasing prevalence of infectious diseases is anticipated to boost the multivalent vaccines market in the future. Infectious diseases are conditions triggered by bacteria, viruses, fungi, or parasites that transmit via direct contact, tainted surfaces, airborne particles, or water. This surge stems from heightened global travel, which speeds up the spread of pathogens internationally. Multivalent vaccines aid in preventing diseases by providing protection against various pathogen strains in one shot, minimizing the requirement for multiple vaccinations and bolstering herd immunity. For example, in April 2024, TravelHealthPro-a UK travel health platform backed by the UK Health Security Agency-reported 2,004 malaria cases in the UK for 2023, compared to 1,369 imported cases the previous year. Thus, the growing rates of infectious diseases are fueling expansion in the multivalent vaccines market.

Major companies in the multivalent vaccines market are prioritizing the development of advanced pentavalent vaccines to broaden immunization coverage, streamline dosing schedules, and enhance public health results. Pentavalent vaccines are multivalent formulations that offer protection against five different pathogens in one dose, cutting down on injections, boosting compliance, and optimizing vaccine distribution efforts. For example, in December 2023, Panacea Biotec Ltd., an India-based biotech firm, introduced EasyFourPol, the world's first fully liquid pentavalent vaccine safeguarding against diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae Type B. It features a ready-to-use format that skips preparation for healthcare providers, cuts clinic visits and immunization expenses, and reduces environmental footprint by decreasing reliance on multiple vials, syringes, and packaging.

In February 2024, AstraZeneca plc, a UK-based pharmaceutical firm, bought Icosavax Inc. for $1.1 billion. This deal bolsters AstraZeneca's vaccine lineup with Icosavax's advanced RSV candidate, IVX-A12, and broadens the company's footprint in the respiratory vaccine sector. It also boosts AstraZeneca's R&D strengths via Icosavax's proprietary protein virus-like particle (VLP) technology, which supports multivalent vaccines against respiratory viruses. Icosavax Inc. is a US-based biotech firm focused on a protein VLP platform for developing multivalent vaccines.

Major companies operating in the multivalent vaccines market are Pfizer Inc., Merck & Co. Inc., Sanofi SA, GlaxoSmithKline plc, Novartis AG, CSL Seqirus, Zydus Lifesciences Limited, Sinovac Biotech Ltd., GC Biopharma Corp., Serum Institute of India Pvt. Ltd., Indian Immunologicals Ltd., Bavarian Nordic, Panacea Biotec Ltd., VBI Vaccines Inc., WestVac Biopharma Co. Ltd., Emergent BioSolutions Inc., Moderna Inc., BioNTech SE, Abbott Laboratories, Boehringer Ingelheim International GmbH

North America was the largest region in the multivalent vaccines market in 2025. The regions covered in the multivalent vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the multivalent vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The multivalent vaccines market consists of sales of bivalent vaccines, trivalent vaccines, and polyvalent vaccines. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Multivalent Vaccines Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses multivalent vaccines market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for multivalent vaccines ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The multivalent vaccines market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Conjugate Vaccines; Inactivated And Subunit Vaccines; Live Attenuated Vaccines; Toxoid Vaccines; Recombinant Vaccines
• 2) By Disease: Influenza; Pneumonia; Hepatitis; Meningitis; Rotavirus
• 3) By Route Of Administration: Oral; Injectable
• 4) By Age Group: Pediatrics; Adults; Geriatrics
• 5) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Subsegments:
• 1) By Conjugate Vaccines: Polysaccharide Conjugate Vaccines; Protein Conjugate Vaccines
• 2) By Inactivated And Subunit Vaccines: Inactivated Whole Virus Vaccines; Subunit Protein Vaccines; Virus-Like Particle Vaccines
• 3) By Live Attenuated Vaccines: Live Attenuated Bacterial Vaccines; Live Attenuated Viral Vaccines
• 4) By Toxoid Vaccines: Diphtheria Toxoid Vaccines; Tetanus Toxoid Vaccines
• 5) By Recombinant Vaccines: Recombinant Protein Vaccines; Recombinant DNA Vaccines
• Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; Sanofi SA; GlaxoSmithKline plc; Novartis AG; CSL Seqirus; Zydus Lifesciences Limited; Sinovac Biotech Ltd.; GC Biopharma Corp.; Serum Institute of India Pvt. Ltd.; Indian Immunologicals Ltd.; Bavarian Nordic; Panacea Biotec Ltd.; VBI Vaccines Inc.; WestVac Biopharma Co. Ltd.; Emergent BioSolutions Inc.; Moderna Inc.; BioNTech SE; Abbott Laboratories; Boehringer Ingelheim International GmbH
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Multivalent Vaccines Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Multivalent Vaccines Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Multivalent Vaccines Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Multivalent Vaccines Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Industry 4.0 & Intelligent Manufacturing
  • 4.1.3 Sustainability, Climate Tech & Circular Economy
  • 4.1.4 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.5 Artificial Intelligence & Autonomous Intelligence
• 4.2. Major Trends
  • 4.2.1 Rising Demand For Broad-Spectrum Immunization
  • 4.2.2 Increasing Focus On Combination Vaccines
  • 4.2.3 Expansion Of Pediatric And Geriatric Vaccination Programs
  • 4.2.4 Growing Adoption Of Preventive Healthcare Measures
  • 4.2.5 Higher Investment In Vaccine R&D Pipelines

5. Multivalent Vaccines Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Vaccination Centers
• 5.3 Pediatric Clinics
• 5.4 Public Health Institutions
• 5.5 Research Institutes

6. Multivalent Vaccines Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Multivalent Vaccines Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Multivalent Vaccines PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Multivalent Vaccines Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Multivalent Vaccines Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Multivalent Vaccines Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Multivalent Vaccines Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Multivalent Vaccines Market Segmentation

• 9.1. Global Multivalent Vaccines Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Conjugate Vaccines, Inactivated And Subunit Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Recombinant Vaccines
• 9.2. Global Multivalent Vaccines Market, Segmentation By Disease, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Influenza, Pneumonia, Hepatitis, Meningitis, Rotavirus
• 9.3. Global Multivalent Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Oral, Injectable
• 9.4. Global Multivalent Vaccines Market, Segmentation By Age Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Pediatrics, Adults, Geriatrics
• 9.5. Global Multivalent Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
• 9.6. Global Multivalent Vaccines Market, Sub-Segmentation Of Conjugate Vaccines, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Polysaccharide Conjugate Vaccines, Protein Conjugate Vaccines
• 9.7. Global Multivalent Vaccines Market, Sub-Segmentation Of Inactivated And Subunit Vaccines, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Inactivated Whole Virus Vaccines, Subunit Protein Vaccines, Virus-Like Particle Vaccines
• 9.8. Global Multivalent Vaccines Market, Sub-Segmentation Of Live Attenuated Vaccines, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Live Attenuated Bacterial Vaccines, Live Attenuated Viral Vaccines
• 9.9. Global Multivalent Vaccines Market, Sub-Segmentation Of Toxoid Vaccines, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Diphtheria Toxoid Vaccines, Tetanus Toxoid Vaccines
• 9.10. Global Multivalent Vaccines Market, Sub-Segmentation Of Recombinant Vaccines, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Recombinant Protein Vaccines, Recombinant DNA Vaccines

10. Multivalent Vaccines Market Regional And Country Analysis

• 10.1. Global Multivalent Vaccines Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Multivalent Vaccines Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Multivalent Vaccines Market

• 11.1. Asia-Pacific Multivalent Vaccines Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Multivalent Vaccines Market, Segmentation By Type, Segmentation By Disease, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Multivalent Vaccines Market

• 12.1. China Multivalent Vaccines Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Multivalent Vaccines Market, Segmentation By Type, Segmentation By Disease, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Multivalent Vaccines Market

• 13.1. India Multivalent Vaccines Market, Segmentation By Type, Segmentation By Disease, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Multivalent Vaccines Market

• 14.1. Japan Multivalent Vaccines Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Multivalent Vaccines Market, Segmentation By Type, Segmentation By Disease, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Multivalent Vaccines Market

• 15.1. Australia Multivalent Vaccines Market, Segmentation By Type, Segmentation By Disease, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Multivalent Vaccines Market

• 16.1. Indonesia Multivalent Vaccines Market, Segmentation By Type, Segmentation By Disease, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Multivalent Vaccines Market

• 17.1. South Korea Multivalent Vaccines Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Multivalent Vaccines Market, Segmentation By Type, Segmentation By Disease, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Multivalent Vaccines Market

• 18.1. Taiwan Multivalent Vaccines Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Multivalent Vaccines Market, Segmentation By Type, Segmentation By Disease, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Multivalent Vaccines Market

• 19.1. South East Asia Multivalent Vaccines Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Multivalent Vaccines Market, Segmentation By Type, Segmentation By Disease, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Multivalent Vaccines Market

• 20.1. Western Europe Multivalent Vaccines Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Multivalent Vaccines Market, Segmentation By Type, Segmentation By Disease, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Multivalent Vaccines Market

• 21.1. UK Multivalent Vaccines Market, Segmentation By Type, Segmentation By Disease, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Multivalent Vaccines Market

• 22.1. Germany Multivalent Vaccines Market, Segmentation By Type, Segmentation By Disease, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Multivalent Vaccines Market

• 23.1. France Multivalent Vaccines Market, Segmentation By Type, Segmentation By Disease, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Multivalent Vaccines Market

• 24.1. Italy Multivalent Vaccines Market, Segmentation By Type, Segmentation By Disease, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Multivalent Vaccines Market

• 25.1. Spain Multivalent Vaccines Market, Segmentation By Type, Segmentation By Disease, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Multivalent Vaccines Market

• 26.1. Eastern Europe Multivalent Vaccines Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Multivalent Vaccines Market, Segmentation By Type, Segmentation By Disease, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Multivalent Vaccines Market

• 27.1. Russia Multivalent Vaccines Market, Segmentation By Type, Segmentation By Disease, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Multivalent Vaccines Market

• 28.1. North America Multivalent Vaccines Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Multivalent Vaccines Market, Segmentation By Type, Segmentation By Disease, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Multivalent Vaccines Market

• 29.1. USA Multivalent Vaccines Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Multivalent Vaccines Market, Segmentation By Type, Segmentation By Disease, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Multivalent Vaccines Market

• 30.1. Canada Multivalent Vaccines Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Multivalent Vaccines Market, Segmentation By Type, Segmentation By Disease, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Multivalent Vaccines Market

• 31.1. South America Multivalent Vaccines Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Multivalent Vaccines Market, Segmentation By Type, Segmentation By Disease, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Multivalent Vaccines Market

• 32.1. Brazil Multivalent Vaccines Market, Segmentation By Type, Segmentation By Disease, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Multivalent Vaccines Market

• 33.1. Middle East Multivalent Vaccines Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Multivalent Vaccines Market, Segmentation By Type, Segmentation By Disease, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Multivalent Vaccines Market

• 34.1. Africa Multivalent Vaccines Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Multivalent Vaccines Market, Segmentation By Type, Segmentation By Disease, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Multivalent Vaccines Market Regulatory and Investment Landscape

36. Multivalent Vaccines Market Competitive Landscape And Company Profiles

• 36.1. Multivalent Vaccines Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Multivalent Vaccines Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Multivalent Vaccines Market Company Profiles
  • 36.3.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

37. Multivalent Vaccines Market Other Major And Innovative Companies

• CSL Seqirus, Zydus Lifesciences Limited, Sinovac Biotech Ltd., GC Biopharma Corp., Serum Institute of India Pvt. Ltd., Indian Immunologicals Ltd., Bavarian Nordic, Panacea Biotec Ltd., VBI Vaccines Inc., WestVac Biopharma Co. Ltd., Emergent BioSolutions Inc., Moderna Inc., BioNTech SE, Abbott Laboratories, Boehringer Ingelheim International GmbH

38. Global Multivalent Vaccines Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Multivalent Vaccines Market

40. Multivalent Vaccines Market High Potential Countries, Segments and Strategies

• 40.1 Multivalent Vaccines Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Multivalent Vaccines Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Multivalent Vaccines Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer